Barclays
BBOT

Barclays’s BridgeBio Oncology BBOT Stock Holding History

Barclays’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16K Buy
2,099
+1,887
+890% +$15.8K ﹤0.01% 4628
2026
Q1 		$1.9K Buy
+212
New +$2.28K ﹤0.01% 4858

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays's BBOT Position: Q2 2026 in Review

Barclays increased its BridgeBio Oncology (BBOT) stake by 890% in Q2 2026, buying an estimated $15.8K and bringing the position to 2,099 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #4628.

Barclays first reported a position in BBOT in Q1 2026 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Barclays held 2,099 shares of BridgeBio Oncology worth $16K as of Q2 2026.
  • Barclays bought 1,887 BridgeBio Oncology shares in Q2 2026, an estimated $15.8K.
  • BridgeBio Oncology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4628 holding.
  • Barclays first reported a position in BridgeBio Oncology in Q1 2026 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.